02.01.18
Level Brands, Inc. has entered into a licensing agreement with Vancouver-based Isodiol International Inc., a bioactive phytoceutical company focused on pharmaceutical and wellness products, to develop consumer products for Kathy Ireland Health & Wellness and for Level Brands subsidiary I’M1, the company’s lifestyle brand for men.
Isodiol’s cannabinoid derived (CBD) products are 99%+ pure, bioactive and pharmaceutical grade. The products include body balm, tincture, skin care, nano-mist and functional beverages.
“One of the many responsibilities in this new venture is, for me personally, to serve as educator in chief about cannabidiol, and how it is used by Isodiol,” said Ireland. “This company is leading the strategy of appropriate uses of hemp derivatives, and Isodiol products are free of THC. It’s ironic that people find controversy in the powerfully useful hemp plant. Without THC, hemp has many natural and important uses, which are beneficial in countless ways. We need people to please understand, that hemp, without THC, is similar to a grape without fermentation. What the Isodiol team has done is, bring the best qualities of hemp-derived CBD to the market without any psychotropic element, whatsoever.”
Martin A. Sumichrast, Level Brands’ CEO, said his firm is excited to work with Isodiol “on developing the highest quality hemp derivatives-based consumable and topical skin care products for Kathy Ireland Health & Wellness and I’M1.”
Level Brands will receive an initial $2 million payment in the form of Isodiol shares and initial cash payments of $62,500 due at execution of the licensing agreement and on June 30, 2018. During the term of the agreement, Level will receive $750,000 each quarter in the form of Isodiol shares and a 3% royalty on all gross sales of branded products. The contract term is for an initial five years. Marketing materials were designed and filmed in December 2017 and both parties were expected to finalize all points of the negotiations no later than Jan. 31, 2018.
Isodiol’s cannabinoid derived (CBD) products are 99%+ pure, bioactive and pharmaceutical grade. The products include body balm, tincture, skin care, nano-mist and functional beverages.
“One of the many responsibilities in this new venture is, for me personally, to serve as educator in chief about cannabidiol, and how it is used by Isodiol,” said Ireland. “This company is leading the strategy of appropriate uses of hemp derivatives, and Isodiol products are free of THC. It’s ironic that people find controversy in the powerfully useful hemp plant. Without THC, hemp has many natural and important uses, which are beneficial in countless ways. We need people to please understand, that hemp, without THC, is similar to a grape without fermentation. What the Isodiol team has done is, bring the best qualities of hemp-derived CBD to the market without any psychotropic element, whatsoever.”
Martin A. Sumichrast, Level Brands’ CEO, said his firm is excited to work with Isodiol “on developing the highest quality hemp derivatives-based consumable and topical skin care products for Kathy Ireland Health & Wellness and I’M1.”
Level Brands will receive an initial $2 million payment in the form of Isodiol shares and initial cash payments of $62,500 due at execution of the licensing agreement and on June 30, 2018. During the term of the agreement, Level will receive $750,000 each quarter in the form of Isodiol shares and a 3% royalty on all gross sales of branded products. The contract term is for an initial five years. Marketing materials were designed and filmed in December 2017 and both parties were expected to finalize all points of the negotiations no later than Jan. 31, 2018.